Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | fatty acid elongase, putative | 0.0318 | 0 | 0.5 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.2451 | 1 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.2451 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0318 | 0 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0318 | 0 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0318 | 0 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.2451 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.2451 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0318 | 0 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.2451 | 1 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.2451 | 1 | 0.5 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.2451 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.